Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK Plc announced a share buyback of £2 billion as it saw better than expected profit in the fourth quarter. The share ...
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...